A Phase II Multi-center Study Evaluating the Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and Sylatron (Peginterferon Alfa-2b)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 14 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2017 Status changed from not yet recruiting to recruiting.
- 19 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 15 Sep 2017.